Fragmentomic analysis of circulating tumor DNA-targeted cancer panelsKyle T. Helzer, Shuang G. Zhao, Marina N. Sharifi et al.|Annals of Oncology|2023Cited by 70
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical OutcomesMarina N. Sharifi, Joshua M. Lang, Jamie M. Sperger et al.|Cancer Discovery|2025Cited by 16
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panelsKyle T. Helzer, Shuang G. Zhao, Marina N. Sharifi et al.|Nature Communications|2025Cited by 9
Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancerJamie M. Sperger, Joshua M. Lang, Amy K. Taylor et al.|Cancer Research|2023Cited by 4
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancerMarina N. Sharifi, Martin Sjöström, Eric Feng et al.|Molecular Oncology|2025Cited by 4